An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6
Steiner, H ; Berger, AP ; Godoy-Tundidor, S ; Bjartell, Anders LU ; Lilja, Hans LU
; Bartsch, G
; Hobisch, A
and Culig, Z
(2004)
In European Journal of Cancer
40(7).
p.1066-1072
- Abstract
- Concentrations of interleukin 6 (IL-6) and its receptor are increased in human prostate cancer. Prostate cancer LNCaP-IL-6+ cells, established after prolonged treatment with IL-6, have been found to acquire a growth advantage. Vascular endothelial growth factor (VEGF) may accelerate the growth of various tumours by stimulation of VEGF receptor 2 (VEGFR-2). To understand better the regulation of proliferation of LNCaP-IL-6+ cells, the expression of VEGF and VEGFR-2 was here investigated in the LNCaP-IL-6+ subline. VEGF was measured in cellular supernatants by enzyme-linked immunoassay. The expression of VEGFR-2 was assessed by Western blot. LNCaP-IL-6+ and control LNCaP-IL-6- cells were treated with a neutralising antibody against VEGFR-2.... (More)
- Concentrations of interleukin 6 (IL-6) and its receptor are increased in human prostate cancer. Prostate cancer LNCaP-IL-6+ cells, established after prolonged treatment with IL-6, have been found to acquire a growth advantage. Vascular endothelial growth factor (VEGF) may accelerate the growth of various tumours by stimulation of VEGF receptor 2 (VEGFR-2). To understand better the regulation of proliferation of LNCaP-IL-6+ cells, the expression of VEGF and VEGFR-2 was here investigated in the LNCaP-IL-6+ subline. VEGF was measured in cellular supernatants by enzyme-linked immunoassay. The expression of VEGFR-2 was assessed by Western blot. LNCaP-IL-6+ and control LNCaP-IL-6- cells were treated with a neutralising antibody against VEGFR-2. VEGF concentrations were 20-fold higher in LNCaP-IL-6+ than in LNCaP-IL-6- cells. The stimulatory effect of IL-6 on VEGF production was abolished by an inhibitor of the signalling pathway for phosphoinositol 3 kinase in LNCaP-IL-6+ and LNCaP-IL-6- cells. Exogenous VEGF did not stimulate proliferation in either LNCaP-IL-6+ cells or controls. VEGFR-2 was detected only in LNCaP-IL-6+ cells, in which the neutralising antibody caused a partial inhibition of cell proliferation. It was concluded that a VEGF autocrine loop is established in prostate cancer cells generated after chronic treatment with IL-6. Because of the upregulation of IL-6 in patients with prostate cancer, these findings might be clinically relevant. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/279074
- author
- Steiner, H
; Berger, AP
; Godoy-Tundidor, S
; Bjartell, Anders
LU
; Lilja, Hans
LU
; Bartsch, G
; Hobisch, A
and Culig, Z
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- factor, autocrine signalling, vascular endothelial growth, interleukin 6, prostate cancer, cytokines
- in
- European Journal of Cancer
- volume
- 40
- issue
- 7
- pages
- 1066 - 1072
- publisher
- Elsevier
- external identifiers
-
- wos:000221467400028
- pmid:15093584
- scopus:1942517751
- pmid:15093584
- ISSN
- 1879-0852
- DOI
- 10.1016/j.ejca.2003.11.033
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Translational Medicine (013017500), Urology (013243400), Clinical Chemistry, Malmö (013016000), Division of Urological Cancers (013243420)
- id
- 4431d3f9-7c0a-4e85-b668-a731c7b127fd (old id 279074)
- date added to LUP
- 2016-04-01 11:49:39
- date last changed
- 2022-01-26 18:52:22
@article{4431d3f9-7c0a-4e85-b668-a731c7b127fd,
abstract = {{Concentrations of interleukin 6 (IL-6) and its receptor are increased in human prostate cancer. Prostate cancer LNCaP-IL-6+ cells, established after prolonged treatment with IL-6, have been found to acquire a growth advantage. Vascular endothelial growth factor (VEGF) may accelerate the growth of various tumours by stimulation of VEGF receptor 2 (VEGFR-2). To understand better the regulation of proliferation of LNCaP-IL-6+ cells, the expression of VEGF and VEGFR-2 was here investigated in the LNCaP-IL-6+ subline. VEGF was measured in cellular supernatants by enzyme-linked immunoassay. The expression of VEGFR-2 was assessed by Western blot. LNCaP-IL-6+ and control LNCaP-IL-6- cells were treated with a neutralising antibody against VEGFR-2. VEGF concentrations were 20-fold higher in LNCaP-IL-6+ than in LNCaP-IL-6- cells. The stimulatory effect of IL-6 on VEGF production was abolished by an inhibitor of the signalling pathway for phosphoinositol 3 kinase in LNCaP-IL-6+ and LNCaP-IL-6- cells. Exogenous VEGF did not stimulate proliferation in either LNCaP-IL-6+ cells or controls. VEGFR-2 was detected only in LNCaP-IL-6+ cells, in which the neutralising antibody caused a partial inhibition of cell proliferation. It was concluded that a VEGF autocrine loop is established in prostate cancer cells generated after chronic treatment with IL-6. Because of the upregulation of IL-6 in patients with prostate cancer, these findings might be clinically relevant.}},
author = {{Steiner, H and Berger, AP and Godoy-Tundidor, S and Bjartell, Anders and Lilja, Hans and Bartsch, G and Hobisch, A and Culig, Z}},
issn = {{1879-0852}},
keywords = {{factor; autocrine signalling; vascular endothelial growth; interleukin 6; prostate cancer; cytokines}},
language = {{eng}},
number = {{7}},
pages = {{1066--1072}},
publisher = {{Elsevier}},
series = {{European Journal of Cancer}},
title = {{An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6}},
url = {{http://dx.doi.org/10.1016/j.ejca.2003.11.033}},
doi = {{10.1016/j.ejca.2003.11.033}},
volume = {{40}},
year = {{2004}},
}